Theravance Biopharma (TBPH) Competitors $14.30 +0.60 (+4.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$14.50 +0.20 (+1.40%) As of 06:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. HCM, BHC, OGN, KNSA, GMTX, CGON, ALVO, CPRX, TARS, and IDYAShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include HUTCHMED (HCM), Bausch Health Cos (BHC), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), Gemini Therapeutics (GMTX), CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Theravance Biopharma vs. Its Competitors HUTCHMED Bausch Health Cos Organon & Co. Kiniksa Pharmaceuticals International Gemini Therapeutics CG Oncology Alvotech Catalyst Pharmaceuticals Tarsus Pharmaceuticals IDEAYA Biosciences Theravance Biopharma (NASDAQ:TBPH) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment. Does the media refer more to TBPH or HCM? In the previous week, Theravance Biopharma had 6 more articles in the media than HUTCHMED. MarketBeat recorded 15 mentions for Theravance Biopharma and 9 mentions for HUTCHMED. Theravance Biopharma's average media sentiment score of 0.80 beat HUTCHMED's score of -0.21 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, TBPH or HCM? Theravance Biopharma has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Do insiders and institutionals believe in TBPH or HCM? 99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, TBPH or HCM? HUTCHMED has higher revenue and earnings than Theravance Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$64.38M11.19-$56.42M$0.2459.58HUTCHMED$630.20M4.96$37.73MN/AN/A Is TBPH or HCM more profitable? Theravance Biopharma has a net margin of 16.88% compared to HUTCHMED's net margin of 0.00%. Theravance Biopharma's return on equity of 6.93% beat HUTCHMED's return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma16.88% 6.93% 3.52% HUTCHMED N/A N/A N/A Do analysts rate TBPH or HCM? Theravance Biopharma currently has a consensus price target of $23.00, indicating a potential upside of 60.84%. HUTCHMED has a consensus price target of $28.00, indicating a potential upside of 56.16%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.60HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryTheravance Biopharma beats HUTCHMED on 12 of the 15 factors compared between the two stocks. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$720.15M$2.54B$5.78B$10.18BDividend YieldN/A57.24%5.73%4.60%P/E Ratio59.5823.6475.6326.02Price / Sales11.19545.33462.3591.38Price / CashN/A27.5625.8129.91Price / Book4.015.3812.766.25Net Income-$56.42M$32.95M$3.29B$270.76M7 Day Performance2.73%1.21%0.86%2.54%1 Month Performance8.75%5.08%4.70%5.73%1 Year Performance75.68%-1.67%69.47%25.85% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma3.353 of 5 stars$14.30+4.4%$23.00+60.8%+75.7%$720.15M$64.38M59.58110News CoverageAnalyst ForecastShort Interest ↑Gap UpHCMHUTCHMED2.6392 of 5 stars$16.11+0.9%$28.00+73.8%+3.7%$2.79B$630.20M0.001,811BHCBausch Health Cos4.5781 of 5 stars$7.33-0.3%$9.00+22.9%+15.0%$2.72B$9.63B28.1720,700Positive NewsOGNOrganon & Co.4.5224 of 5 stars$10.48+0.9%$17.33+65.5%-48.0%$2.70B$6.40B3.894,000Positive NewsKNSAKiniksa Pharmaceuticals International2.1117 of 5 stars$36.57+2.4%$41.17+12.6%+46.9%$2.65B$423.24M914.48220Short Interest ↑GMTXGemini TherapeuticsN/A$60.76+0.9%N/A+25.2%$2.63BN/A-60.7630CGONCG Oncology2.0237 of 5 stars$33.69+1.9%$53.91+60.0%-4.2%$2.52B$1.14M-19.0361High Trading VolumeALVOAlvotech3.7556 of 5 stars$8.16-2.0%$14.00+71.6%-25.7%$2.51B$491.98M35.481,032Short Interest ↓CPRXCatalyst Pharmaceuticals4.9621 of 5 stars$20.08-1.0%$33.20+65.3%-1.2%$2.48B$491.73M12.1780Positive NewsAnalyst DowngradeTARSTarsus Pharmaceuticals2.3783 of 5 stars$56.89-1.3%$66.67+17.2%+48.4%$2.43B$182.95M-24.4250IDYAIDEAYA Biosciences3.9712 of 5 stars$23.39-13.9%$45.77+95.7%-34.3%$2.38B$7M-6.1780Trending NewsAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies HCM Alternatives BHC Alternatives OGN Alternatives KNSA Alternatives GMTX Alternatives CGON Alternatives ALVO Alternatives CPRX Alternatives TARS Alternatives IDYA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TBPH Stock Alerts